Nadroparin therapy in pediatric patients with venous thromboembolic disease

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 3, 2008, Pages 230-234

  Van Ommen, C Heleen ^a   Van Den Dool, Erik Jan ^a   Peters, Marjolein ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Nadroparin; Pediatrics; Safety; Venous thromboembolism

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; NADROPARIN;

ADOLESCENCE; ADOLESCENT; AGE DISTRIBUTION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHILD; CHILDHOOD DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFANT; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEWBORN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; NADROPARIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 41849084864     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31816356f8     Document Type: Article

References (28)

1. Gibson BE, Chalmers E, Bolton-Maggs P, et al. Thromboembolism in childhood: a prospective two year BPSU study in the United Kingdom. February 2001 to February 2003. Thromb Haemost. 2003;1(suppl 1):OC422.
2. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83:1251-1257.
3. Hofmann S, Knoefler R, Lorenz N, et al. Clinical experiences with low-molecular weight heparins in pediatric patients. Thromb Res. 2001;103:345-353.
4. Laporte S, Mismetti P, Piquet P, et al. Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. Eur J Pharm Sci. 1999;8:119-125.
5. Davis R, Faulds D. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging. 1997;10:299-322.
6. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 suppl):64S-94S.
7. Newall F, Bauman ME. Point-of-care monitoring of anticoagulant therapy in paediatric patients. Progr Pediatr Cardiol. 2005;21:53-61.
8. Hettiarachchi RJ, Prins MH, Lensing AW, et al. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr Opin Pulm Med. 1998;4:220-225.
9. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996;334:682-687.
10. Albisetti M, Andrew M. Low molecular weight heparin in children. Eur J Pediatr. 2002;161:71-77.
11. Massicotte MP. Low-molecular-weight heparin therapy in children. J Pediatr Hematol Oncol. 2001;23:189-194.
12. Sutor AH, Chan AKC, Massicotte P. Low-molecular-weight heparin in pediatric patients. Sem Thromb Hemost. 2004;30:31-39.
13. Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr. 2000;136:439-445.
14. Kuhle S, Massicotte P, Dinyari M, et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost. 2005;94:1164-1171.
15. Massicotte P, Adams M, Marzinotto V, et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr. 1996;128:313-318.
16. Massicotte P, Julian JA, Marzinotto V, et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res. 2003;109:93-99.
17. Nohe N, Flemmer A, Rumler R, et al. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr. 1999;158:S134-S139.
18. Punzalan RC, Hillery CA, Montgomery RR, et al. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol. 2000;22:137-142.
19. Merkel N, Gunther G, Schobess R. Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients. Acta Haematol. 2006;115:230-236.
20. Michaels LA, Gurian M, Hegyi T, et al. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant. Pediatrics. 2004;114:703-707.
21. Streif W, Goebel G, Chan AK, et al. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed. 2003;88:F365-F370.
22. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res. 1994;35:78-83.
23. Bonduel M, Sciuccati G, Hepner M, et al. Acenocoumarol therapy in pediatric patients. J Thromb Haemost. 2003;1:1740-1743.
24. Mismetti P, Laporte-Simitsidis S, Navarro C, et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost. 1998;79:1162-1165.
25. Dunaway KK, Gal P, Ransom JL. Use of enoxaparin in a preterm infant. Ann Pharmacother. 2000;34:1410-1413.
26. Schobess R, During C, Bidlingmaier C, et al. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica. 2006;91:1701-1704.
27. Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res. 2003;109:85-92.
28. van Ommen CH, Heijboer H, van den Dool EJ, et al. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost. 2003;1:2516-2522.